Scarica l'app Stockscreener
1.31
7.09%
-0.10
Precedente Chiudi:
$1.41
Aprire:
$1.34
Volume 24 ore:
1.10M
Relative Volume:
0.50
Capitalizzazione di mercato:
$80.22M
Reddito:
$5.03M
Utile/perdita netta:
$-185.41M
Rapporto P/E:
-0.4239
EPS:
-3.09
Flusso di cassa netto:
$-139.79M
1 W Prestazione:
-13.25%
1M Prestazione:
-5.07%
6M Prestazione:
-88.22%
1 anno Prestazione:
-90.92%
Intervallo 1D:
$1.28
$1.35
Intervallo di 1 settimana:
$1.242
$1.56
Portata 52W:
$1.242
$16.52
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Nome
Pliant Therapeutics Inc
Settore
Industria
Telefono
650-481-6770
Indirizzo
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Confronta PLRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.31 | 80.22M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-04 | Ripresa | Cantor Fitzgerald | Neutral |
| 2025-03-04 | Downgrade | Needham | Buy → Hold |
| 2025-03-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | Downgrade | Stifel | Buy → Hold |
| 2025-02-10 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | Downgrade | Citigroup | Buy → Neutral |
| 2025-02-10 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-02-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-02-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-05-18 | Iniziato | Canaccord Genuity | Buy |
| 2023-04-13 | Iniziato | Robert W. Baird | Outperform |
| 2022-12-14 | Iniziato | Stifel | Buy |
| 2022-12-07 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-07-20 | Iniziato | SVB Leerink | Outperform |
| 2022-05-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Iniziato | Oppenheimer | Outperform |
| 2021-11-24 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-11-03 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-20 | Iniziato | BTIG Research | Buy |
| 2021-04-05 | Iniziato | Citigroup | Buy |
| 2020-06-29 | Iniziato | Citigroup | Buy |
| 2020-06-29 | Iniziato | Cowen | Outperform |
| 2020-06-29 | Iniziato | Needham | Buy |
| 2020-06-29 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Pliant Therapeutics Inc Borsa (PLRX) Ultime notizie
Pliant Therapeutics: An Activist On Deck - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
PLRX stock touches 52-week low at $1.25 amid sharp annual decline - Investing.com India
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus
PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know - MSN
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Pliant Therapeutics – PLRX - MENAFN.COM
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant ... - Bluefield Daily Telegraph
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - GlobeNewswire Inc.
TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Pliant Therapeutics Inc - GuruFocus
Pliant discontinues Phase 2b/3 trial of IPF treatment bexotegrast - Pulmonary Fibrosis News
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus.com
Pliant Therapeutics (NASDAQ:PLRX) Receives “Neutral” Rating from HC Wainwright - Defense World
Pliant Therapeutics Announces Interim Phase 1 Data for - GlobeNewswire
Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types - Benzinga
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - Markets Insider
Pliant Therapeutics Says Experimental Cancer Drug Shows Antitumor Activity in Phase 1 Trial - Marketscreener.com
Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’ - Yahoo Finance
Pliant Pops Poison Pill as Concentra Threat Looms - BioSpace
Pliant Therapeutics adopts shareholder rights plan By Investing.com - Investing.com Australia
Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor - The Business Journals
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - The Malaysian Reserve
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus
Pliant Therapeutics Signs Shareholder Rights Agreement -March 13, 2025 at 08:32 am EDT - Marketscreener.com
Pliant Therapeutics adopts shareholder rights plan - Investing.com India
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement - The Manila Times
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement to Protect Shareholder Interests - Nasdaq
Pliant Therapeutics Shields Against Hostile Takeover with Strategic Rights Plan - StockTitan
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Pliant Therapeutics - MENAFN.COM
Pliant dives 49% as it abandons phase 2 trial of bexotegrast for IPF - MSN
Pliant Therapeutics (NASDAQ:PLRX) Cut to “Hold” at Leerink Partnrs - Defense World
Leerink Partners Downgrades Pliant Therapeutics (MUN:9PT) - Nasdaq
If You Don’t Bullish On Pliant Therapeutics Inc (NASDAQ: PLRX) Now, You’ll Regret Your Decision Later - Stocks Register
Pliant halts lung fibrosis trial amid safety concerns - The Pharma Letter
Pliant Therapeutics (NASDAQ:PLRX) Price Target Cut to $3.00 by Analysts at Royal Bank of Canada - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc- PLRX - PR Newswire
Leerink Partners Downgrades Pliant Therapeutics (PLRX) - MSN
Pliant Therapeutics stock tumbles amid IPF trial cancellation - MSN
Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future - Benzinga
Hold Rating on Pliant Therapeutics Amid Trial Discontinuation and Safety Concerns - TipRanks
Pliant Therapeutics Inc Azioni (PLRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):